Invivyd

Contributing Author

Recent Articles by Invivyd

11 hours	Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA and Provides an Update on Next Steps with the U.S. FDA IVVD -6.69% GlobeNewswire
Jul-02	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IVVD GlobeNewswire
Jun-16	Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine IVVD GlobeNewswire
Jun-09	Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration IVVD GlobeNewswire
Jun-03	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IVVD GlobeNewswire
Jun-01	Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID IVVD +7.02% GlobeNewswire
May-27	Invivyd to Participate in Upcoming Investor Events IVVD GlobeNewswire
May-14	Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights IVVD -21.09% GlobeNewswire
May-11	Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination IVVD GlobeNewswire
May-07	Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 IVVD GlobeNewswire
May-05	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IVVD -5.44% GlobeNewswire
Apr-20	Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit IVVD GlobeNewswire
Apr-09	Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles IVVD +31.85% GlobeNewswire
Apr-07	Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health IVVD GlobeNewswire
Apr-06	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IVVD GlobeNewswire
Mar-30	Invivyd Announces Presentation at the World Vaccine Congress Washington IVVD -13.14% IVVD +9.24% GlobeNewswire
Mar-05	Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates IVVD GlobeNewswire
Mar-05	Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer IVVD GlobeNewswire
Mar-02	Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 IVVD IVVD -5.81% GlobeNewswire
Mar-02	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IVVD IVVD -5.81% GlobeNewswire
Feb-24	New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies IVVD GlobeNewswire
Feb-03	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration IVVD +8.05% GlobeNewswire
Jan-22	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention IVVD GlobeNewswire
Jan-20	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 IVVD -8.57% GlobeNewswire
Jan-08	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights IVVD GlobeNewswire
Dec-23	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID IVVD GlobeNewswire
Dec-23	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID IVVD GlobeNewswire
Nov-25	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference IVVD -5.42% GlobeNewswire
Nov-24	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness IVVD GlobeNewswire
Nov-17	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants IVVD -10.92% GlobeNewswire
Nov-17	Invivyd Announces Proposed Public Offering of Common Stock IVVD +20.85% IVVD -10.92% GlobeNewswire
Nov-06	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights IVVD GlobeNewswire
Nov-03	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 IVVD -8.52% IVVD -13.04% GlobeNewswire
Oct-28	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID IVVD GlobeNewswire
Oct-06	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID IVVD +22.41% GlobeNewswire
Sep-24	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors IVVD +5.17% IVVD -6.56% GlobeNewswire
Sep-17	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer IVVD -8.73% GlobeNewswire
Sep-04	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 IVVD GlobeNewswire
Aug-27	Invivyd to Participate in Upcoming Investor Conferences IVVD -15.44% GlobeNewswire
Aug-22	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares IVVD IVVD +7.61% GlobeNewswire
Aug-20	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants IVVD -16.71% GlobeNewswire
Aug-20	Invivyd Announces Proposed Public Offering of Common Stock IVVD +11.00% IVVD -16.71% GlobeNewswire
Aug-18	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") IVVD -17.82% GlobeNewswire
Aug-14	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights IVVD IVVD -11.54% GlobeNewswire
Aug-14	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 IVVD IVVD -11.54% GlobeNewswire
Jul-23	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome IVVD +5.26% GlobeNewswire
Jul-21	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population IVVD GlobeNewswire
Jul-02	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome IVVD GlobeNewswire
Jun-26	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection IVVD +13.43% GlobeNewswire
May-27	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus IVVD +20.15% GlobeNewswire
May-23	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas IVVD GlobeNewswire
May-21	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 IVVD -5.52% GlobeNewswire
May-15	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights IVVD -15.78% GlobeNewswire
May-14	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy IVVD GlobeNewswire
May-13	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference IVVD GlobeNewswire
May-12	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles IVVD +29.67% GlobeNewswire
May-08	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 IVVD GlobeNewswire

Invivyd

Recent Articles by Invivyd

Upgrade your Finviz experience